DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets

British Journal of Pharmacology

Volumn 158, Issue 3, 2009, Pages 679-692

  Li, Long Shan ^a   Morales, Julio C ^a   Veigl, Martina ^b   Sedwick, David ^c   Greer, Sheldon ^d   Meyers, Mark ^a   Wagner, Mark ^a   Fishel, Richard ^e   Boothman, David A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

5 fluorouracil; DNA mismatch repair; HMLH1; Hypermethylation; MMR c Abl p73 GADD45 signalling; Thymidylate synthase

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE; FLUCYTOSINE DEOXYRIBOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; MERCAPTOPURINE; METHYLNITRONITROSOGUANIDINE; METHYLNITROSOUREA; PROCARBAZINE; PROTEIN MLH1; RALTITREXED; TEMOZOLOMIDE; TETRAHYDRODEOXYURIDINE; TETRAHYDROURIDINE; TIOGUANINE;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DEATH; COLON TUMOR; COLORECTAL CANCER; CYTOTOXICITY; DNA DAMAGE; DRUG METABOLISM; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE FUNCTION; GENETIC CONSERVATION; HUMAN; LETHALITY; METHYLATION; MISMATCH REPAIR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIZATION; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DNA MISMATCH REPAIR; FLUOROURACIL; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 70350070732     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00423.x     Document Type: Review

References (138)

1. Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT et al. (1996). hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 93 : 13629 13634.
2. Acharya S, Foster PL, Brooks P, Fishel R (2003). The coordinated functions of the E. coli MutS and MutL proteins in mismatch repair. Mol Cell 12 : 233 246.
3. Aebersold PM (1979). Mutation induction by 5-fluorodeoxyuridine in synchronous Chinese hamster cells. Cancer Res 39 : 808 810.
4. Allen DJ, Makhov A, Grilley M, Taylor J, Thresher R, Modrich P et al. (1997). MutS mediates heteroduplex loop formation by a translocation mechanism. EMBO J 16 : 4467 4476.
5. Ban C, Yang W (1998). Structural basis for MutH activation in E. coli mismatch repair and relationship of MutH to restriction endonucleases. EMBO J 17 : 1526 1534.
6. Ban C, Junop M, Yang W (1999). Transformation of MutL by ATP binding and hydrolysis: a switch in DNA mismatch repair. Cell 97 : 85 97.
7. Bellacosa A (2001). Role of MED1 (MBD4) gene in DNA repair and human cancer. J Cell Physiol 187 : 137 144.
8. Bellacosa A, Cicchillitti L, Schepis F, Riccio A, Yeung AT, Matsumoto Y et al. (1999). MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc Natl Acad Sci USA 96 : 3969 3974.
9. Berardini M, Mazurek A, Fishel R (2000). The effect of O6-methylguanine DNA adducts on the adenosine nucleotide switch functions of hMSH2-hMSH6 and hMSH2-hMSH3. J Biol Chem 275 : 27851 27857.
10. Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM et al. (2006). Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice. Clin Cancer Res 12 : 7483 7491.
11. Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ et al. (2008). Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol 62 : 363 368.
12. Blackwell LJ, Bjornson KP, Modrich P (1998). DNA-dependent activation of the hMutSalpha ATPase. J Biol Chem 273 : 32049 32054.
13. Boothman DA, Briggle TV, Greer S (1985). Metabolic channeling of 5-fluoro-2′-deoxycytidine utilizing inhibitors of its deamination in cell culture. Mol Pharmacol 27 : 584 594.
14. Boothman DA, Briggle TV, Greer S (1987a). Protective, tumor-selective dual pathway activation of 5-fluoro-2′-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755. Cancer Res 47 : 2344 2353.
15. Boothman DA, Briggle TV, Greer S (1987b). Tumor-selective metabolism of 5-fluoro-2′-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. Cancer Res 47 : 2354 2362.
16. Boothman DA, Briggle TV, Greer S (1989). Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. Pharmacol Ther 42 : 65 88.
17. Caradonna SJ, Cheng YC (1980). The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells. Mol Pharmacol 18 : 513 520.
18. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT et al. (2004). Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126 : 394 401.
19. Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS et al. (2005). Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 4 : 1515 1520.
20. Compere SJ, Palmiter RD (1981). DNA methylation controls the inducibility of the mouse metallothionein-I gene lymphoid cells. Cell 25 : 233 240.
21. Cooper DL, Lahue RS, Modrich P (1993). Methyl-directed mismatch repair is bidirectional. J Biol Chem 268 : 11823 11829.
22. Das SK, Benditt EP, Loeb LA (1983). Rapid changes in deoxynucleoside triphosphate pools in mammalian cells treated with mutagens. Biochem Biophys Res Commun 114 : 458 464.
23. Davis TW, Wilson-Van Patten C, Meyers M, Kunugi KA, Cuthill S, Reznikoff C et al. (1998). Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 58 : 767 778.
24. Dolnick BJ, Pink JJ (1983). 5-fluorouracil modulation of dihydrofolate reductase RNA levels in methotrexate-resistant KB cells. J Biol Chem 258 : 13299 13306.
25. Dolnick BJ, Pink JJ (1985). Effects of 5-fluorouracil on dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells. J Biol Chem 260 : 3006 3014.
26. Drummond JT, Li GM, Longley MJ, Modrich P (1995). Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science 268 : 1909 1912.
27. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N et al. (2000). p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 58 : 52 59.
28. Fishel R (1998). Mismatch repair, molecular switches, and signal transduction. Genes Dev 12 : 2096 2101.
29. Fishel R (1999). Signaling mismatch repair in cancer. Nat Med 5 : 1239 1241.
30. Fishel R (2001). The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res 61 : 7369 7374.
31. Fishel RA, Kolodner R (1983). Gene conversion in Escherichia coli: the identification of two repair pathways for mismatched nucleotides. UCLA Symp Mol Cell Biol New Series 11 : 309 324.
32. Fishel RA, Siegel EC, Kolodner R (1986). Gene conversion in Escherichia coli. Resolution of heteroallelic mismatched nucleotides by co-repair. J Mol Biol 188 : 147 157.
33. Fram RJ, Cusick PS, Wilson JM, Marinus MG (1985). Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage. Mol Pharmacol 28 : 51 55.
34. Friedberg E, Walker G, Siede W, Wood R, Schultz R, Ellenberger T (2006). DNA Repair and Mutagenesis. ASM press : Washington DC.
35. Genschel J, Modrich P (2003). Mechanism of 5′-directed excision in human mismatch repair. Mol Cell 12 : 1077 1086.
36. Genschel J, Littman SJ, Drummond JT, Modrich P (1998). Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. J Biol Chem 273 : 19895 19901.
37. Glazer PM, Sarkar SN, Chisholm GE, Summers WC (1987). DNA mismatch repair detected in human cell extracts. Mol Cell Biol 7 : 218 224.
38. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr., Levrero JY et al. (1999). The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399 : 806 809.
39. Gradia S, Acharya S, Fishel R (1997). The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. Cell 91 : 995 1005.
40. Gradia S, Subramanian D, Wilson T, Acharya S, Makhov A, Griffith J et al. (1999). hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA. Mol Cell 3 : 255 261.
41. Gradia S, Acharya S, Fishel R (2000). The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular switch. J Biol Chem 275 : 3922 3930.
42. Grilley M, Welsh KM, Su SS, Modrich P (1989). Isolation and characterization of the Escherichia coli mutL gene product. J Biol Chem 264 : 1000 1004.
43. Grilley M, Griffith J, Modrich P (1993). Bidirectional excision in methyl-directed mismatch repair. J Biol Chem 268 : 11830 11837.
44. Guerrette S, Wilson T, Gradia S, Fishel R (1998). Interactions of human hMSH2 with hMSH3 and hMSH2 with hMSH6: examination of mutations found in hereditary nonpolyposis colorectal cancer. Mol Cell Biol 18 : 6616 6623.
45. Guerrette S, Acharya S, Fishel R (1999). The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer. J Biol Chem 274 : 6336 6341.
46. Haber LT, Walker GC (1991). Altering the conserved nucleotide binding motif in the Salmonella typhimurium MutS mismatch repair protein affects both its ATPase and mismatch binding activities. EMBO J 10 : 2707 2715.
47. Haug T, Skorpen F, Aas PA, Malm V, Skjelbred C, Krokan HE (1998). Regulation of expression of nuclear and mitochondrial form of human uracil-DNA glycosylase. Nucleic Acids Res 26 : 1449 1457.
48. Heidelberger C, Danenberg PV, Moran RG (1983). Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol 54 : 58 119.
49. Heinen CD, Wilson T, Mazurek A, Berardini M, Butz C, Fishel R (2002). HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch functions. Cancer Cell 1 : 469 478.
50. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H (2000). Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119 : 921 928.
51. Hess MT, Gupta RD, Kolodner RD (2002). Dominant Saccharomyces cerevisiae msh6 mutations cause increased mispair binding and decreased dissociation from mispairs by Msh2-Msh6 in the presence of ATP. J Biol Chem 277 : 25545 25553.
52. Hickman MJ, Samson LD (1999). Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 96 : 10764 10769.
53. Holmes J Jr., Clark S, Modrich P (1990). Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci USA 87 : 5837 5841.
54. Hopkins RL, Goodman MF (1980). Deoxyribonucleotide pools, base pairing, and sequence configuration affecting bromodeoxyuridine- and 2-aminopurine- induced mutagenesis. Proc Natl Acad Sci USA 77 : 1801 1805.
55. Imai K, Slupphaug G, Lee W-I, Revy P, Nonoyama S, Catalan N et al. (2003). Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 4 : 1023 1028.
56. Ingraham HA, Tseng BY, Goulian M (1980). Mechanism for exclusion of 5-fluorouracil from DNA. Cancer Res 40 : 998 1001.
57. Irving JA, Hall AG (2001). Mismatch repair defects as a cause of resistance to cytotoxic drugs. Expert Rev Anticancer Ther 1 : 149 158.
58. Johnston PG, Takimoto CH, Grem JL, Chabner BA, Allegra CJ, Chu E (1996). Antimetabolites. Cancer Chemother Biol Response Modif 16 : 1 27.
59. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J et al. (2006). Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55 : 848 855.
60. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J et al. (2009). The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45 : 365 373.
61. Kadyrov FA, Dzantiev L, Constantin N, Modrich P (2006). Endonucleolytic function of MutLalpha in human mismatch repair. Cell 126 : 297 308. (Pubitemid 44092957)
62. Karran P (2001). Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22 : 1931 1937.
63. Karran P, Marinus MG (1982). Mismatch correction at O6-methylguanine residues in E. coli DNA. Nature 296 : 868 869.
64. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51 : 6304 6311.
65. Kolodner RD, Mendillo ML, Putnam CD (2007). Coupling distant sites in DNA during DNA mismatch repair. Proc Natl Acad Sci USA 104 : 12953 12954.
66. Krokan HE, Nilsen H, Skorpen F, Otterlei M, Slupphaug G (2000). Base excision repair of DNA in mammalian cells. FEBS Lett 476 : 73 77.
67. Krokan HE, Drablos F, Slupphaug G (2002). Uracil in DNA - occurrence, consequences and repair. Oncogene 21 : 8935 8948.
68. van Laar JA, van der Wilt CL, Rustum YM, Noordhuis P, Smid K, Pinedo HM et al. (1996). Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. Clin Cancer Res 2 : 1327 1333.
69. van Laar JA, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ (1998). Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 34 : 296 306.
70. Lahue RS, Su SS, Modrich P (1987). Requirement for d(GATC) sequences in Escherichia coli mutHLS mismatch correction. Proc Natl Acad Sci USA 84 : 1482 1486.
71. Lahue RS, Au KG, Modrich P (1989). DNA mismatch correction in a defined system. Science 245 : 160 164. (Pubitemid 19193931)
72. Lamers MH, Perrakis A, Enzlin JH, Winterwerp HH, de Wind N, Sixma TK (2000). The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch. Nature 407 : 711 717.
73. Li GM, Modrich P (1995). Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc Natl Acad Sci USA 92 : 1950 1954.
74. Li LS, Kim NG, Kim SH, Park C, Kim H, Kang HJ et al. (2003). Chromosomal imbalances in the colorectal carcinomas with microsatellite instability. Am J Pathol 163 : 1429 1436.
75. Li LS, Morales JC, Hwang A, Wagner MW, Boothman DA (2008). DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediated apoptosis. J Biol Chem 283 : 21394 21403.
76. Lin DP, Wang Y, Scherer SJ, Clark AB, Yang K, Avdievich E et al. (2004). An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 64 : 517 522.
77. Lindahl T, Nyberg B (1974). Heat-induced deanimation of cytosine residues in deoxyribonucleic acid. Biochemistry 13 : 3405 3410.
78. Lu AL, Clark S, Modrich P (1983). Methyl-directed repair of DNA base-pair mismatches in vitro. Proc Natl Acad Sci USA 80 : 4639 4643.
79. Matson SW (1986). Escherichia coli helicase II (urvD gene product) translocates unidirectionally in a 3′ to 5′ direction. J Biol Chem 261 : 10169 10175.
80. Mazurek A, Berardini M, Fishel R (2002). Activation of human MutS homologs by 8-oxo-guanine DNA damage. J Biol Chem 277 : 8260 8266.
81. Mazurek A, Johnson CN, Germann MW, Fishel R (2009). Sequence context effect for hMSH2-hMSH6 mismatch-dependent activation. Proc Natl Acad Sci USA 106 : 4177 4182.
82. Mekras JA, Boothman DA, Perez LM, Greer S (1984). Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Res 44 : 2551 2560.
83. Meyers M et al. (1996). Loss of DNA mismatch repair reveals resistance to 5-fluorouracil. AACR Abstract.
84. Meyers M, Theodosiou M, Acharya S, Odegaard E, Wilson T, Lewis JE et al. (1997). Cell cycle regulation of the human DNA mismatch repair genes hMSH2, hMLH1, and hPMS2. Cancer Res 57 : 206 208.
85. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA (2001). Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61 : 5193 5201.
86. Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD et al. (2003). A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 22 : 7376 7388.
87. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA (2005). DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280 : 5516 5526.
88. Modrich P (1989). Methyl-directed DNA mismatch correction. J Biol Chem 264 : 6597 6600.
89. Modrich P (1991). Mechanisms and biological effects of mismatch repair. Annu Rev Genet 25 : 229 253.
90. Modrich P (1997). Strand-specific mismatch repair in mammalian cells. J Biol Chem 272 : 24727 24730.
91. Modrich P, Lahue R (1996). Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 65 : 101 133.
92. Natrajan G, Lamers MH, Enzlin JH, Winterwerp HHK, Perrakis A, Sixma TK (2003). Structures of Escherichia coli DNA mismatch repair enzyme MutS in complex with different mismatches: a common recognition mode for diverse substrates. Nucleic Acids Res 31 : 4814 4821.
93. Newman CN, Miller JH (1983). Mutagen-induced changes in cellular deoxycytidine triphosphate and thymidine triphosphate in Chinese hamster ovary cells. Biochem Biophys Res Commun 114 : 34 40.
94. Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Kawabata K et al. (1991). Relationship of in vivo antitumor activities of fluorinated pyrimidines to thymidylate synthase activity and intratumoral concentrations of 5-fluorouracil and uracil. Anticancer Res 11 : 607 612.
95. Obmolova G, Ban C, Hsieh P, Yang W (2000). Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature 407 : 703 710.
96. Orlandi L, Bearzatto A, Abolafio G, De Marco C, Daidone MG, Zaffaroni N (1999). Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer 81 : 252 260.
97. Otterlei M, Haug T, Nagelhus TA, Slupphaug G, Lindmo T, Krokan HE (1998). Nuclear and mitochondrial forms of human uracil-DNA glycosylase contains complex nuclear localisation and a strong classical mitochondrial localisation signal, respecticely. Nucleic Acids Res 26 : 4611 4617.
98. Palombo F, Iaccarino I, Nakajima E, Ikejima M, Shimada T, Jiricny J (1996). hMutSbeta, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA. Curr Biol 6 : 1181 1184.
99. Parker BO, Marinus MG (1992). Repair of DNA heteroduplexes containing small heterologous sequences in Escherichia coli. Proc Natl Acad Sci USA 89 : 1730 1734.
100. Parker WB, Cheng YC (1990). Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48 : 381 395.
101. Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Stoerker J, Genuardi M et al. (2000). Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase. J Biol Chem 275 : 32422 32429.
102. Pluciennik A, Modrich P (2007). Protein roadblocks and helix discontinuities are barriers to the initiation of mismatch repair. Proc Natl Acad Sci USA 104 : 12709 12713.
103. Prem veer Reddy G, Pardee AB (1980). Multienzyme complex for metabolic channeling in mammalian DNA replication. Proc Natl Acad Sci USA 77 : 3312 3316.
104. Rada C, Williams GT, Nilsen H, Barnes DE, Lindahl T, Neuberger MS (2002). Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Curr Biol 12 : 1748 1755.
105. Raschle M, Marra G, Nystrom-Lahti M, Schar P, Jiricny J (1999). Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1. J Biol Chem 274 : 32368 32375.
106. veer Reddy GP, Pardee AB (1982). Coupled ribonucleoside diphosphate reduction, channeling, and incorporation into DNA of mammalian cells. J Biol Chem 257 : 12526 12531.
107. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al. (2003). Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 : 247 257.
108. Rydberg B (1978). Bromouracil mutagenesis and mismatch repair in mutator strains of Escherichia coli. Mutat Res 52 : 11 24.
109. Sancar A (1995). DNA repair in humans. Annu Rev Genet 29 : 69 105.
110. Santi DV (1980). Perspective on the design and biochemical pharmacology of inhibitors of thymidylate synthetase. J Med Chem 23 : 103 111.
111. Schmutte C, Marinescu RC, Sadoff MM, Guerrette S, Overhauser J, Fishel R (1998). Human exonuclease I interacts with the mismatch repair protein hMSH2. Cancer Res 58 : 4537 4542.
112. Schmutte C, Sadoff MM, Shim KS, Acharya S, Fishel R (2001). The interaction of DNA mismatch repair proteins with human exonuclease I. J Biol Chem 276 : 33011 33018.
113. Shapiro R (ed. 1981) Damage to DNA Caused by Hydrolysis. Platium Press : New York.
114. Smith SS, Kaplan BE, Sowers LC, Newman EM (1992). Mechanism of human methyl-directed DNA methyltransferase and the fidelity of cytosine methylation. Proc Natl Acad Sci USA 89 : 4744 4748.
115. Sobrero AF, Aschele C, Bertino JR (1997). Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 15 : 368 381.
116. Spiegelman S, Nayak R, Sawyer R, Stolfi R, Martin D (1980a). Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA. Cancer 45 : 1129 1134.
117. Spiegelman S, Sawyer R, Nayak R, Ritzi E, Stolfi R, Martin D (1980b). Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc Natl Acad Sci USA 77 : 4966 4970.
118. Sprang SR (1997). G protein mechanisms: insights from structural analysis. Annu Rev Biochem 66 : 639 678.
119. Su SS, Modrich P (1986). Escherichia coli mutS-encoded protein binds to mismatched DNA base pairs. Proc Natl Acad Sci USA 83 : 5057 5061.
120. Thomas DC, Roberts JD, Kunkel TA (1991). Heteroduplex repair in extracts of human HeLa cells. J Biol Chem 266 : 3744 3751.
121. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S et al 1998). Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 95 : 8698 8702.
122. Viswanathan M, Lovett ST (1998). Single-strand DNA-specific exonucleases in Escherichia coli. Roles in repair and mutation avoidance. Genetics 149 : 7 16.
123. Wagner MW, Li LS, Morales JC, Galindo CL, Garner HR, Bornmann WG et al. (2008). Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses. J Biol Chem 283 : 21382 21393.
124. Wagner R Jr., Meselson M (1976). Repair tracts in mismatched DNA heteroduplexes. Proc Natl Acad Sci USA 73 : 4135 4139.
125. Wang JY, Edelmann W (2006). Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell 9 : 417 418.
126. Warren JJ, Pohlhaus TJ, Changela A, Iyer RR, Modrich PL, Beese LS (2007). Structure of the human MutSalpha DNA lesion recognition complex. Mol Cell 26 : 579 592.
127. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG et al. (2001). Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344 : 1196 1206.
128. Welsh KM, Lu AL, Clark S, Modrich P (1987). Isolation and characterization of the Escherichia coli mutH gene product. J Biol Chem 262 : 15624 15629.
129. Wildenberg J, Meselson M (1975). Mismatch repair in heteroduplex DNA. Proc Natl Acad Sci USA 72 : 2202 2206.
130. Willmore E, Durkacz BW (1993). Cytotoxic mechanisms of 5-fluoropyrimidines. Relationships with poly(ADP-ribose) polymerase activity, DNA strand breakage and incorporation into nucleic acids. Biochem Pharmacol 46 : 205 211.
131. Wilson T, Guerrette S, Fishel R (1999). Dissociation of mismatch recognition and ATPase activity by hMSH2-hMSH3. J Biol Chem 274 : 21659 21664.
132. Wurzer JC, Tallarida RJ, Sirover MA (1994). New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells. J Pharmacol Exp Ther 269 : 39 43.
133. Yamaguchi M, Dao V, Modrich P (1998). MutS and MutL activate DNA helicase II in a mismatch-dependent manner. J Biol Chem 273 : 9197 9201.
134. Yang G, Scherer SJ, Shell SS, Yang K, Kim M, Lipkin M et al. (2004). Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 6 : 139 150.
135. Yin MB, Guo B, Panadero A, Frank C, Wrzosek C, Slocum HK et al. (1999). Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex. Exp Cell Res 247 : 189 199.
136. Yoshioka K, Yoshioka Y, Hsieh P (2006). ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell 22 : 501 510.
137. Zhang H, Richards B, Wilson T, Lloyd M, Cranston A, Thorburn A et al. (1999). Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 59 : 3021 3027.
138. Zhang Y, Yuan F, Presnell SR, Tian K, Gao Y, Tomkinson AE et al. (2005). Reconstitution of 5′-directed human mismatch repair in a purified system. Cell 122 : 693 705.